Treatment of oral ranula in HIV-positive patient.
HIV-associated salivary gland disease
Human immunodeficiency virus (HIV)
OK-423 sclerotherapy
Ranula
Sclerotherapy
Journal
Auris, nasus, larynx
ISSN: 1879-1476
Titre abrégé: Auris Nasus Larynx
Pays: Netherlands
ID NLM: 7708170
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
30
08
2019
revised:
06
02
2020
accepted:
11
02
2020
pubmed:
10
4
2020
medline:
21
10
2021
entrez:
10
4
2020
Statut:
ppublish
Résumé
HIV-associated salivary gland disease refers to the pathology in head and neck lesions such as ranula, salivary gland swelling, xerostomia, and benign lymphoepithelial cysts in the parotid gland. Here, we present a unique case of the ranula patient with HIV infection treated with OK-423 sclerotherapy. Case report: The patient was a 42-year-old Japanese male with a few months history of oral floor swelling. Computed tomography (CT) showed a low-density area limited within the right floor of the mouth. Magnetic resonance imaging (MRI) revealed a distinct T2-high intensity area localized on the same location. The puncture fluid was bloody mucus, and the cytology was no malignancy. We diagnosed a simple ranula. He was, however, found to be HIV-antibody positive at the examination before treatment by chance. He was referred to the department of infectious diseases and definitively diagnosed HIV infection by western blot. We chose OK-432 sclerotherapy because of its minimally invasive and the risk of HIV infecting medical staff. Two times OK-432 injection made the lesion disappear. Conclusion: The case indicated that OK-432 sclerotherapy could be effective for ranula related to HIV.
Identifiants
pubmed: 32269001
pii: S0385-8146(20)30040-7
doi: 10.1016/j.anl.2020.02.009
pii:
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
171-174Informations de copyright
Copyright © 2020. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare no conflict of interest.